Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 3
2002 3
2003 2
2004 4
2005 3
2006 3
2007 4
2008 7
2009 4
2010 6
2011 8
2012 7
2013 1
2014 8
2015 5
2016 5
2017 7
2018 9
2019 11
2020 12
2021 14
2022 19
2023 22
2024 28
2025 34
2026 24

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

221 results

Results by year

Filters applied: . Clear all
Page 1
Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management.
Castells M, Butterfield J. Castells M, et al. J Allergy Clin Immunol Pract. 2019 Apr;7(4):1097-1106. doi: 10.1016/j.jaip.2019.02.002. J Allergy Clin Immunol Pract. 2019. PMID: 30961835 Review.
Patients with clonal mast cell activation syndromes (MCAS) including cutaneous and systemic mastocytosis (SM) may present with symptoms of mast cell activation, but in addition can have organ damage from the local effects of tissue infilt …
Patients with clonal mast cell activation syndromes (MCAS) including cutaneous and systemic mastocytosis (SM) may prese …
Chronic Spontaneous Urticaria: A Review.
Kolkhir P, Bonnekoh H, Metz M, Maurer M. Kolkhir P, et al. JAMA. 2024 Nov 5;332(17):1464-1477. doi: 10.1001/jama.2024.15568. JAMA. 2024. PMID: 39325444 Review.
Known autoimmune endotypes (subtypes of urticaria defined by distinct pathogenesis) of chronic spontaneous urticaria are mediated by mast cell-activating IgE and/or IgG autoantibodies (>50%). Approximately 40% of patients with chronic spontaneous urticaria …
Known autoimmune endotypes (subtypes of urticaria defined by distinct pathogenesis) of chronic spontaneous urticaria are mediated by mast …
Omalizumab for mast cell disorders.
Akin C. Akin C. J Allergy Clin Immunol. 2025 Jan;155(1):81-83. doi: 10.1016/j.jaci.2024.11.004. Epub 2024 Nov 13. J Allergy Clin Immunol. 2025. PMID: 39542144 No abstract available.
Urticaria and Angioedema: an Update on Classification and Pathogenesis.
Radonjic-Hoesli S, Hofmeier KS, Micaletto S, Schmid-Grendelmeier P, Bircher A, Simon D. Radonjic-Hoesli S, et al. Clin Rev Allergy Immunol. 2018 Feb;54(1):88-101. doi: 10.1007/s12016-017-8628-1. Clin Rev Allergy Immunol. 2018. PMID: 28748365 Free article. Review.
Urticaria is a common, mast cell-driven disease presenting with wheals or angioedema or both. In the last years, urticaria has increasingly attracted notice to clinicians and researchers, last but not least inspired by the approval of omalizumab, an anti-IgE …
Urticaria is a common, mast cell-driven disease presenting with wheals or angioedema or both. In the last years, urticaria has …
Autoimmune chronic spontaneous urticaria.
Kolkhir P, Muñoz M, Asero R, Ferrer M, Kocatürk E, Metz M, Xiang YK, Maurer M. Kolkhir P, et al. J Allergy Clin Immunol. 2022 Jun;149(6):1819-1831. doi: 10.1016/j.jaci.2022.04.010. J Allergy Clin Immunol. 2022. PMID: 35667749 Review.
Chronic spontaneous urticaria (CSU) is a debilitating mast cell-driven disease characterized by recurrent wheals and/or angioedema. Substantial progress has been made in dissecting the 2 main autoimmune mechanisms that drive the pathogenesis of CSU. ...Type IIb auto …
Chronic spontaneous urticaria (CSU) is a debilitating mast cell-driven disease characterized by recurrent wheals and/or angioe …
Omalizumab may not inhibit mast cell and basophil activation in vitro.
Gericke J, Ohanyan T, Church MK, Maurer M, Metz M. Gericke J, et al. J Eur Acad Dermatol Venereol. 2015 Sep;29(9):1832-6. doi: 10.1111/jdv.12693. Epub 2014 Sep 26. J Eur Acad Dermatol Venereol. 2015. PMID: 25257818 Review.
Recently, it has been suggested that most CSU patients have an autoimmune aetiology which may lead to chronic activation of mast cells and basophils. OBJECTIVE: To understand more of the mechanisms by which omalizumab may exert its effects in CSU, its …
Recently, it has been suggested that most CSU patients have an autoimmune aetiology which may lead to chronic activation of mast …
Mast Cell Activation Syndrome.
Frieri M. Frieri M. Clin Rev Allergy Immunol. 2018 Jun;54(3):353-365. doi: 10.1007/s12016-015-8487-6. Clin Rev Allergy Immunol. 2018. PMID: 25944644 Review.
Mast cell activation syndrome (MCAS) involves the skin, gastrointestinal, cardiovascular, respiratory, and neurologic systems, classified as primary, secondary, and idiopathic. ...A recent global classification is a response of clinical symptoms, a substantia …
Mast cell activation syndrome (MCAS) involves the skin, gastrointestinal, cardiovascular, respiratory, and neurologic s …
Systematic review of omalizumab for refractory clonal and non-clonal mast cell activation syndrome.
Matheny MV, Craig T, Al-Shaikhly T. Matheny MV, et al. Allergy Asthma Proc. 2025 Jan 1;46(1):11-18. doi: 10.2500/aap.2025.46.240076. Allergy Asthma Proc. 2025. PMID: 39741373
Background: Patients with mast cell activation syndrome (MCAS) can be refractory to standard antimediator therapy. ...Conclusion: The majority of patients with refractory MCAS reported in the literature had a reduction in mast cell mediator-rela …
Background: Patients with mast cell activation syndrome (MCAS) can be refractory to standard antimediator therapy. ...C …
Urticaria.
Kolkhir P, Giménez-Arnau AM, Kulthanan K, Peter J, Metz M, Maurer M. Kolkhir P, et al. Nat Rev Dis Primers. 2022 Sep 15;8(1):61. doi: 10.1038/s41572-022-00389-z. Nat Rev Dis Primers. 2022. PMID: 36109590 Review.
It presents with wheals, angioedema or both due to activation and degranulation of skin mast cells and the release of histamine and other mediators. ...Current urticaria treatment aims at complete response, with a stepwise approach using second-generation H1 …
It presents with wheals, angioedema or both due to activation and degranulation of skin mast cells and the release of h …
Idiopathic Anaphylaxis.
Ben-Shoshan M, Cem A, Cook VE, Khalaf R, Freigeh G. Ben-Shoshan M, et al. J Allergy Clin Immunol Pract. 2025 Dec;13(12):3165-3178.e1. doi: 10.1016/j.jaip.2025.08.019. Epub 2025 Aug 27. J Allergy Clin Immunol Pract. 2025. PMID: 40882893 Free article. Review.
IA remains a diagnosis of exclusion, requiring careful consideration of IgE-mediated allergies, cofactor-dependent anaphylaxis, clonal mast cell disorders, and systemic mimics such as neuroendocrine tumors or vasovagal syncope. ...Although antihistamines and cortico …
IA remains a diagnosis of exclusion, requiring careful consideration of IgE-mediated allergies, cofactor-dependent anaphylaxis, clonal ma …
221 results